{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027449","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.797925+00:00","generated_at":"2026-06-11T17:01:20.563405+00:00","sec_items":["2.02","4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Daré Bioscience Q2 2023 cash $13.3M; auditor resigns; Ovaprene Phase 3 enrollment to start 4Q23","bullets":["Cash and cash equivalents of $13.3M at June 30, 2023; G&A expenses $2.9M, R&D expenses $6.0M.","Auditor Mayer Hoffman McCann P.C. resigned effective upon filing of 2023 10-K or earlier; no disagreements; prior report had going concern paragraph.","XACIATO first commercial sale expected 2H-2023; $1.0M cash received and $1.8M milestone upon first sale from partner Organon.","Ovaprene pivotal Phase 3 contraceptive efficacy study enrollment to start 4Q-2023; U.S. rights licensed to Bayer.","Sildenafil Cream 3.6% positive Phase 2b topline data; preparing end-of-Phase 2 FDA meeting for FSAD/FSIAD."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027449","json":"https://secwatch.observer/filing/0001493152-23-027449.json","markdown":"https://secwatch.observer/filing/0001493152-23-027449.md","text":"https://secwatch.observer/filing/0001493152-23-027449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223027449/0001493152-23-027449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223027449/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:01:20.563405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42de5b7e9ef520c15d40d7bf11db520505b560c8","claim":"Dare Bioscience, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223027449/0001493152-23-027449-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}